logo-loader

Kazia Therapeutics bolsters pipeline with new first-in-class oncology drug candidate

Published: 11:05 27 Apr 2021 AEST

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott soon after entering into a worldwide exclusive licensing agreement as well as a master services agreement with Evotec SE (FRA:EVT) – a leading European drug discovery and development company. The agreement was made for EVT801 – a small molecule, first-in class oncology drug candidate, for which Kazia expects to launch a phase-I clinical trial in 2021.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

6 hours, 55 minutes ago